DMKPQ (DMK Pharmaceuticals) Buildings And Improvements: $ Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Buildings And Improvements?

DMK Pharmaceuticals DMKPQ -99.00% 16 Buildings And Improvements is $ Mil as of Sep. 2023. GuruFocus rates DMKPQ with a GF Score™ of 16/100.

DMK Pharmaceuticals Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Buildings And Improvements Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 3.04 - - -

DMK Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $ Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Buildings And Improvements of $ Mil as of Sep. 2023. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Buildings And Improvements too high?
DMK Pharmaceuticals' current Buildings And Improvements is $ Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Buildings And Improvements compare to CNNC and THCT?
DMK Pharmaceuticals' Buildings And Improvements of $ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Drug Manufacturers company?
A good Buildings And Improvements depends on the Drug Manufacturers industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Buildings And Improvements is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Buildings And Improvements of $ Mil. The current Buildings And Improvements is $ Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Buildings And Improvements is $ Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price